- Q2 2024 Biora Therapeutics Inc Earnings Call TranscriptAug 12, 2024$0.5833 (-1.35%)Earnings
- Q1 2024 Biora Therapeutics Inc Earnings Call TranscriptMay 15, 2024$0.715 (-3.10%)Earnings
- Q4 2023 Biora Therapeutics Inc Earnings Call TranscriptMar 26, 2024$1.33 (+9.02%)Earnings
- Q3 2023 Biora Therapeutics Inc Earnings Call TranscriptNov 13, 2023$1.37 (-3.52%)Earnings
- Q2 2023 Biora Therapeutics Inc Earnings Call TranscriptAug 14, 2023$3.17 (-8.38%)Earnings
- Biora Therapeutics Inc Annual Shareholders Meeting TranscriptJun 14, 2023
- Q1 2023 Biora Therapeutics Inc Earnings Call TranscriptMay 15, 2023$3.35 (-10.90%)Earnings
- Q4 2022 Biora Therapeutics Inc Earnings Call TranscriptMar 30, 2023$2.67 (+0.75%)Earnings
- Biora Therapeutics Inc Extraordinary Shareholders Meeting TranscriptDec 19, 2022
- Q3 2022 Biora Therapeutics Inc Earnings Call TranscriptNov 14, 2022$7.03 (+0.75%)Earnings
- Q2 2022 Biora Therapeutics Inc Earnings Call TranscriptAug 15, 2022$26 (+4.00%)Earnings
- Biora Therapeutics Inc Annual Shareholders Meeting TranscriptJun 15, 2022
- Q1 2022 Biora Therapeutics Inc Earnings Call TranscriptMay 10, 2022$19.27 (+1.43%)Earnings
- Q4 2021 Progenity Inc Earnings Call TranscriptMar 28, 2022$40.25 (-4.73%)Earnings
- Q3 2021 Progenity Inc Earnings Call TranscriptNov 10, 2021$88 (+3.23%)Earnings
- Q2 2021 Progenity Inc Earnings Call TranscriptAug 12, 2021$43.5 (-3.87%)Earnings
- Progenity Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 22, 2021
- Progenity Inc Call to Discuss Strategic Transformation TranscriptJun 02, 2021
- Q1 2021 Progenity Inc Earnings Call TranscriptMay 13, 2021$58.75 (-1.67%)Earnings
- Q4 2020 Progenity Inc Earnings Call TranscriptMar 18, 2021$109.75 (-11.85%)Earnings
- Progenity Inc Preeclampsia Virtual R&D Day TranscriptNov 20, 2020
- Q3 2020 Progenity Inc Earnings Call TranscriptNov 09, 2020$121.75 (-0.20%)Earnings
- Q2 2020 Progenity Inc Earnings Call TranscriptAug 13, 2020$223.75 (-1.97%)Earnings
Progenity Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Good morning, everyone. Thanks for joining us at the Raymond James Human Health Innovation Conference. I'm Andrew Cooper, and I cover diagnostics here for Raymond James.
And we are excited and happy to have Progenity joining us this morning. The Company is in the midst of a little bit of a transition here, exiting the genetic testing market -- or reproductive health market a little bit to focus on the pipeline that's really exciting, most immediately in -- with its preeclampsia rule-out test that I'm sure we'll talk about. And then really some interesting assets in drug delivery and sampling and testing in a pill-based platform, primarily targeting the GI and GI tract initially.
So I'm joined by CEO, Harry Stylli; and CFO, Eric d'Esparbes. (Conference Instructions) Maybe to start, I'm going to turn it over to Harry just to give us a little bit of flavor on where you were, where you are today, what's changed over the last few months that led to this decision to make a little bit of a transition, and what has you most excited
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)